The Impact of Pretransplant Respiratory Virus Detection on Posttransplant Outcomes in Children Undergoing Hematopoietic Cell Transplantation

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Apr 26

PMID 38666501

Authors

Sara Ruth Kim

Anna Nordlander

Hu Xie

Yae-Jean Kim

Chikara Ogimi

Monica S Thakar

Wendy Leisenring

Janet A Englund

Michael Boeckh

Alpana Waghmare

Affiliations

Soon will be listed here.

Abstract

Background: Pretransplant respiratory virus (RV) infections have been associated with negative transplant outcomes in adult hematopoietic cell transplantation (HCT) recipients. In the era of HCT delay because of high-risk RVs, we examined the impact of pretransplant RV detection on transplant outcomes in pediatric HCT recipients.

Methods: This retrospective cohort study included pediatric myeloablative allogeneic HCT recipients from 2010 to 2019. All patients were screened for RV at least once within 90 days before HCT using reverse transcriptase polymerase chain reaction (PCR), regardless of symptoms. Posttransplant outcomes included days alive and out of hospital and progression to lower respiratory tract infection (LRTI).

Results: Among 310 patients, 134 had an RV detected in the 90 days before HCT. In univariable analysis, transplant factors including younger age, total body irradiation, umbilical cord blood transplantation, lymphocyte count <100/mm3, HCT comorbidity index score ≥3, and viral factors including symptomatic infection, human rhinovirus as a virus type, and symptomatic pretransplant upper respiratory tract infection were associated with fewer days alive and out of hospital. In multivariable analysis, transplant factors remained significant, but not viral factors. There was a higher incidence of progression to posttransplant LRTI with the same pretransplant RV if the last positive PCR before HCT was ≤30 days compared with >30 days (P = .007).

Conclusions: In the setting of recommending HCT delay for high-risk RVs, symptomatic upper respiratory tract infection, including human rhinovirus infections, may lead to increased duration of hospitalization and early progression to LRTI when transplantation is performed within 30 days of the last positive PCR test.

References

Kim Y, Waghmare A, Xie H, Holmberg L, Pergam S, Jerome K . Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes. Blood Adv. 2022; 6(18):5307-5316. PMC: 9631699. DOI: 10.1182/bloodadvances.2021004915. View

McIntosh K, Perlman S, Monto A, Englund J . A Proposal to Refer to Four Coronaviruses of Limited Human Virulence "Common Cold Coronaviruses". J Infect Dis. 2022; 226(12):2047-2049. PMC: 9494316. DOI: 10.1093/infdis/jiac355. View

Mowrer C, Lee B, Goyal R, Selvarangan R, Schuster J . Outcome of children with rhinovirus detection prior to allogeneic hematopoietic cell transplant. Pediatr Transplant. 2018; 22(8):e13301. PMC: 7167694. DOI: 10.1111/petr.13301. View

Ljungman P, Ward K, Crooks B, Parker A, Martino R, Shaw P . Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001; 28(5):479-84. DOI: 10.1038/sj.bmt.1703139. View

Campbell A, Guthrie K, Englund J, Farney R, Minerich E, Kuypers J . Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015; 61(2):192-202. PMC: 4565994. DOI: 10.1093/cid/civ272. View

Ogimi C, Xie H, Waghmare A, Jerome K, Leisenring W, Ueda Oshima M . Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant. 2022; 57(4):649-657. PMC: 8853301. DOI: 10.1038/s41409-022-01575-z. View

Schuster J, Banerjee D, Ahmed I, Selvarangan R . Frequency of asymptomatic and symptomatic respiratory virus detection in pediatric hematopoietic cell transplant patients. Pediatr Transplant. 2020; 24(6):e13732. DOI: 10.1111/petr.13732. View

Hijano D, Maron G, Hayden R . Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant. Front Microbiol. 2019; 9:3097. PMC: 6299032. DOI: 10.3389/fmicb.2018.03097. View

Chemaly R, Ghosh S, Bodey G, Rohatgi N, Safdar A, Keating M . Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006; 85(5):278-287. DOI: 10.1097/01.md.0000232560.22098.4e. View

10.

Ottaviano G, Lucchini G, Breuer J, Furtado-Silva J, Lazareva A, Ciocarlie O . Delaying haematopoietic stem cell transplantation in children with viral respiratory infections reduces transplant-related mortality. Br J Haematol. 2019; 188(4):560-569. PMC: 7161889. DOI: 10.1111/bjh.16216. View

11.

Waghmare A, Campbell A, Xie H, Seo S, Kuypers J, Leisenring W . Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013; 57(12):1731-41. PMC: 3840404. DOI: 10.1093/cid/cit639. View

12.

Erard V, Chien J, Kim H, Nichols W, Flowers M, Martin P . Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006; 193(12):1619-25. PMC: 7110078. DOI: 10.1086/504268. View

13.

Broglie L, Friend B, Chhabra S, Logan B, Bupp C, Schiller G . Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. Transplant Cell Ther. 2022; 29(2):125.e1-125.e9. PMC: 9911359. DOI: 10.1016/j.jtct.2022.11.020. View

14.

Fisher B, Danziger-Isakov L, Sweet L, Munoz F, Maron G, Tuomanen E . A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. J Pediatric Infect Dis Soc. 2017; 7(4):275-282. PMC: 7107490. DOI: 10.1093/jpids/pix051. View

15.

Dallmeyer L, Schuz M, Fragkou P, Omony J, Krumbein H, Dimopoulou D . Epidemiology of respiratory viruses among children during the SARS-CoV-2 pandemic: A systematic review and meta-analysis. Int J Infect Dis. 2023; 138:10-18. DOI: 10.1016/j.ijid.2023.10.023. View

16.

Renaud C, Xie H, Seo S, Kuypers J, Cent A, Corey L . Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013; 19(8):1220-6. PMC: 3752411. DOI: 10.1016/j.bbmt.2013.05.005. View

17.

Friend B, Broglie L, Logan B, Chhabra S, Bupp C, Schiller G . Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022; 29(2):123.e1-123.e10. PMC: 9911376. DOI: 10.1016/j.jtct.2022.11.019. View

18.

Ogimi C, Xie H, Waghmare A, Jerome K, Leisenring W, Milano F . Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients. J Clin Virol. 2022; 150-151:105152. PMC: 9206235. DOI: 10.1016/j.jcv.2022.105152. View

19.

Choi S, Xie H, Campbell A, Kuypers J, Leisenring W, Boudreault A . Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. J Infect Dis. 2012; 206(12):1872-7. PMC: 3502377. DOI: 10.1093/infdis/jis610. View

20.

Seo S, Xie H, Leisenring W, Kuypers J, Sahoo F, Goyal S . Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018; 25(1):163-171. PMC: 6310631. DOI: 10.1016/j.bbmt.2018.08.021. View